Three high temperature-sensitive (ts) mutants of foot-and-mouth disease virus were characterized by their relative abilities to grow at 33 or 38.5 C, to kill infant mice, to infect guinea pigs, and to produce foot-and-mouth disease in steers. Mutants ts-24 and ts-42 did not grow at 38.5 C; both may have produced considerable quantities of noninfectious virus particles at 33 C. A third mutant, ts-22, appeared "leaky" because it multiplied to a limited extent during prolonged incubation at the nonpermissive temperature. Mutant ts-42 was pathogenic for infant mice, whereas ts-22 and ts-24 were essentially apathogenic. Mice were protected against the lethal effects of the wild-type (wt) virus if injected 1 week earlier with ts-22, apparently as a result of specific antibody development. One-half of the guinea pigs injected with the mutant viruses showed lesion development, but only at the site of injection. Antibody development was also much less than in those animals injected with the wt virus. The onset of FMD in steers was delayed and the severity of the disease was diminished after intradermalingual injection of the mutant viruses.
Temperature-sensitive (ts) mutants of viruses are unable to produce infectious progeny at elevated (nonpermissive) temperatures (NPT) but multiply at a lower (permissive) temperature (PT). Such conditional-lethal mutants have been used in genetic and biochemical studies of several viruses (8, (13) (14) (15) and recently have been tested for efficacy in live-virus influenza vaccine trials (10) .
Attempts to use living viruses attenuated by high tissue culture passage or adaptation to abnormal host systems in the control of footand-mouth disease (FMD) have not been encouraging (1, 12) . Recently, however, several investigators have described some ts mutants of FMD virus and have suggested using such mutants in live-virus vaccines (5, 16) . This report describes the application of a simple procedure (6, 13) 
RESULTS
Growth of ts mutants. Twenty-one potential ts mutants were recovered after mutagenesis and three were selected for additional study. Data relative to the tissue culture growth characteristics and mouse lethality are given in Table 1 . The titers of the mutants were consistently lower than those of the wt virus when assayed at the PT. The plaque size of ts-22 was comparable with that of the wt and 1 to 2 mm larger than that of the other mutants. When the mutants were grown at the NPT, however, the plaque size of wt was much larger than that of ts-22, the only mutant able to produce plaques at this elevated temperature. Mutants ts-22 and ts-24 showed greatly reduced pathogenicity for infant mice (maximum titers of 2.5 LD5dml); ts-42, however, showed only slight or no reduction in expected mouse lethality.
The growth of these viruses at the PT and NPT was studied over a 72-h period and assayed at the PT (Fig. 1) . Maximum wt virus production was reached within 16 h at the NPT but was delayed until 32 h at the PT. Each of the mutant viruses also developed maximum titers within 28 to 32 h at the PT. Neither ts-24 nor ts-42 multiplied at the NPT, ts-22 replicated to a limited extent at the NPT, and the amount of released virus gradually increased after 16 h. Samples of ts-22 obtained after 72 h at the NPT also were assayed at the NPT and in mice. Plaque yields were similar to those obtained in the PT assays (about 103 PFU/ml), yet this virus was still essentially apathogenic for mice.
Mouse resistance induced by a ts mutant.
Three groups of infant mice were injected with Only one steer injected with a mutant virus (ts-22) showed any clinical signs (tongue lesions) on PID 1; moreover, the blood sample from this steer was the only one that contained virus (104 PFU/ml) that was apathogenic for infant mice. All except one steer eventually developed viremia, and these blood samples contained virus that not only killed mice but that also plaqued equally well at the NPT or the PT. Furthermore, the temporal development of the disease was accompanied by a gradual increase in the mean plaque size of the recovered virus. All steers developed either a febrile response or tongue lesions. Several small vesicles developed on the tongues of the two steers injected with ts-42, but these lesions were less severe than those observed with the other viruses. All steers had similar antibody titers (about 103 3 PD50 values) at the time of necropsy on the day 16 after inoculation. Also, at this time all steers showed evidence of having had moderate to extensive foot lesions. DISCUSSION Three ts mutants initially were selected because of their reduced ability to replicate at the NPT. They appeared, therefore, deficient in at least one gene product necessary in the development of infectious virus particles at the elevated temperature (5, 18, 20) . Such a defect would be expressed either as the nonproduction of a protein or as the production of a protein that would be nonfunctional at the NPT.
Successful use of a ts mutant as a living vaccine depends upon sufficient in vivo replication of the mutant virus to stimulate antibody production without initiating a debilitating disease. Pathogenicity, or lack thereof, may be a reflection of the extent to which these thermosensitive viral-associated reactions occur in the animal. Susceptibility to viral infection may be controlled by the cell genome (9) . However, the ability of a given virus to replicate within a particular cell (in vivo or in vitro) could be considered to be an alterable characteristic of the virus.
The data presented in Table 1 suggest that the inability of the virus to form plaques at 38.5 C is not necessarily associated with its ability to kill infant mice. Mutant ts-42, unable to produce plaques at the NPT, retained its mouse pathogenicity. Conversely, ts-22 produced a limited number of plaques at the NPT (perhaps a "leaky" mutant) (10) but is deficient in mouse lethality. Because ts-24 neither grew at the NPT nor killed mice, both altered characteristics are apparently present in this mutant. Thus, mutants ts-22 and ts-24, in addition to being temperature sensitive, have a second genetic marker, that of mouse apathogenicity.
Although ts-42 apparently replicates in mice, it is unable to multiply in guinea pigs after tongue injection (no lesion or antibody development). All mutants multiplied to a limited extent after foot-pad injections. The temperature inside the tongue is higher than in the footpad (15); thus, temperature apparently was a significant factor. Altered mouse pathogenicity is not related to bovine infectivity. All three mutants produced FMD in steers after intradermalingual injection, although onset of the disease was delayed and its severity reduced. Apparently, in vivo conditions permitted limited replication of the mutant virus. Only the viremia sample obtained on PID 1 with ts-22 (Table 4) was apathogenic for mice. Thereafter the virus population shifted away from the mutant toward the wt phenotype.
The in vivo (bovine) conditions were selective for virus exhibiting wt characteristics, as indicated by the changes in mouse pathogenicity and plaque morphology of the viruses recovered from these steers on successive days after infection. Elevated temperature alone may not have been the factor responsible for these reversions to wt; even after 3 days of growth at the NPT (Fig. 1 ) the mutants retained their original growth characteristics for tissue culture and mice.
PD,0 determinations require virus pathogenic for mice (e.g., wt), whereas antibody assays using the original ts mutants as challenge virus can be performed only at the PT. At least 100-fold higher concentrations of antisera were required to effectively neutralize numbers of mutant plaque-forming particles comparable with the numbers required with the wt virus (Table 3 ). This finding suggests that ts-24 and ts-42 contain relatively high proportions of noninfectious, antibody-reactive material or that they are antigenically distinct from the parental wt virus. Antigenic divergence from the wt characteristic cannot be too great, however, because mutant ts-22 induced specific resistance in mice against subsequent wt infection ( 
